Kliman Gilbert H sold $475K of GKOS

Stifel reiterated a Buy rating and $190 price target for Glaukos (GKOS), citing strong iDose growth and positive payer mix results. GKOS shares have risen 94% over the past year. The company reported Q2 2026 revenue of $185.6M, up 49.5% YoY. Analysts have raised price targets, with Truist setting the highest at $215.

Glaukos Corporation (GKOS) licensed RO-104, a tri-specific biologic for retinal diseases, from RevOpsis Therapeutics. The deal grants GKOS exclusive rights to RevOpsis' RevMod platform for up to four additional candidates. GKOS stock fell 6.3% post-announcement but is up 42.8% year-to-date. The agreement aims to expand GKOS' retinal therapeutics pipeline and market presence.

Glaukos Corp (GKOS) reported positive phase 4 trial results for its iDose TR implant, showing significant reduction in intraocular pressure. The company trades at a P/S ratio of 15.24, above historical and industry medians, reflecting growth expectations. It has a GF Score of 79, indicating strong growth and financial health despite unprofitability. Insiders sold $67.8M in shares over the past year, while institutional investors increased holdings.

Glaukos (NYSE:GKOS) reported positive Phase 4 trial results for its iDose TR therapy combined with cataract surgery. The treatment reduced intraocular pressure by 11.1 mmHg vs. 7.4 mmHg for surgery alone, meeting primary efficacy goals. The study showed no serious safety issues. The therapy aims to improve patient compliance with long-lasting drug delivery. GKOS shares are up 0.12% at $161.49.

Glaukos Corp. reported positive Phase 4 results for its iDose TR glaucoma treatment, meeting the primary endpoint and showing superiority in reducing intraocular pressure. The company also secured an exclusive licensing agreement with RevOpsis Therapeutics for retinal disease treatments. Shares of Glaukos (GKOS) were trading at $161.16 with a $9.5 billion market cap.

Glaukos Corp. (GKOS) reported that its iDose TR implant met the primary goal in a phase 4 trial, reducing mean diurnal intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company announced topline data from the study.